Abstract
Thor has been identified as a new type of gene involved in Drosophila host immune defense. Thor is a member of the 4E-binding protein (4E-BP) family, which in mammals has been defined as critical regulators in a pathway that controls initiation of translation through binding eukaryotic initiation factor 4E (eIF4E). Without an infection, Thor is expressed during all developmental stages and transcripts localize to a wide variety of tissues, including the reproductive system. In response to bacterial infection and, to a lesser extent, by wounding, Thor is up-regulated. The Thor promoter has the canonical NFκB and associated GATA recognition sequences that have been shown to be essential for immune induction, as well as other sequences commonly found for Drosophila immune response genes, including interferon-related regulatory sequences. In survival tests, Thor mutants show symptoms of being immune compromised, indicating that Thor may be critical in host defense. In contrast to Thor, Drosophila eIF4E is not induced by bacterial infection. These findings for Thor provide the first evidence that a 4E-BP family member has a role in immune induction in any organism. Further, no gene in the translation initiation pathway that includes 4E-BP has been previously found to be immune induced. Our results suggest either a role for translational regulation in humoral immunity or a new, nontranslational function for 4E-BP type genes.
Analysis of immunity in Drosophila and other insects has increasingly shown similarities with other organisms and revealed that innate immunity is an ancient defense mechanism (for review, see refs. 1–4). The insect immune response has cellular and humoral components hallmarked, respectively, by the mobilization of hemocytes and production of antimicrobial proteins. Focusing on the humoral component, molecular genetic investigations in Drosophila have revealed that the Toll dorso–ventral-signaling pathway is used not only in Drosophila immunity but in mammalian and plant immunity as well (for review, see ref. 4). Drosophila differentiates between types of infections, and the Toll pathway is critical for antifungal defense, whereas the gene immune deficiency (imd) is critical for antibacterial defense (5, 6). The antimicrobial genes induced through these pathways follow accordingly, being antifungal, such as Drosomycin, or antibacterial, such as Cecropin, Diptericin, and Defensin, and many of these genes have similar family members in other organisms as well (for review, see refs. 3 and 4).
The situation in Drosophila is not nearly so straightforward, however, as both Toll and 18wheeler (18w), which are similar to the mammalian interleukin-1 receptor (IL-1R), also are involved in the antibacterial response (6, 7). In addition, the response varies by the individual antibacterial protein gene, with the extent of induction modulated by the type of bacteria (8). Further, some signaling pathway components are also up-regulated by infection to some degree, such as Toll, 18w, and the NFκB homolog Dorsal-related immunity factor (Dif) (6, 7, 9). These observations indicate a highly complex and sophisticated response to immune challenges.
To identify new genes involved in the immune response, we undertook a genetic screen in Drosophila designed to detect genes that are up-regulated by bacterial infection without a bias for the type of gene selected or the phenotype of a corresponding mutant (10). We selected for strains carrying a single P-element-enhancer trap insertion that showed an increase in B-galactosidase after an infection. One new gene was identified by the screen, named Thor, and postulated to encode a nonantibacterial protein (10). We now report the molecular characterization and mutant phenotype of Thor.
Thor is a member of the 4E-binding protein (4E-BP) family. Mammalian 4E-binding proteins have been defined as critical regulators in a pathway that controls initiation of translation (for review, see refs. 11 and 12). The role of 4E-BP hinges on its binding and sequestration of eukaryotic initiation factor 4E (eIF4E). When 4E-BP is bound to eIF4E, eIF4E cannot bind appropriately to form the translation initiation complex; phosphorylation of 4E-BP releases eIF4E, and translation is then permitted. The results with Thor provide evidence of a 4E-BP family member being involved in immune induction of Drosophila or other organisms. Further, no gene in this translation initiation pathway has been previously found to be immune induced. Our results suggest either a role for translational regulation in humoral immunity or a new, nontranslational function for 4E-BP type genes.
Materials and Methods
Drosophila Stocks.
Oregon R flies were used as the standard wild-type strain. Thor1 carries an insertion of P{lacW}, as described in ref. 10 and Results, and imd was identified from a laboratory stock as described in refs. 5 and 6. To produce stocks to test for the effects of mutation of Thor, both a wild-type revertant, Thor1rv1, and an additional Thor mutant, Thor2, were derived from Thor1 by P-element mobilization as in ref. 10.
Infection Experiments.
Bacteria used were Escherichia coli, Enterobacter cloacae B12 (E. cloacae B12), Staphylococcus epidermidis, and Micrococcus roseus. Bacterial growth and injections of flies were handled as in ref. 10, and survival experiments were conducted as described in ref. 6 with the exception that flies were tested for 4 days.
Molecular Genetic Analysis.
Genomic DNA flanking the Thor P-element insertion site was recovered by the plasmid rescue technique (13). DNA preparation, restriction mapping, and high stringency Southern blots were performed as described in ref. 14. DNA fragments for sequencing were subcloned into the Bluescript vector (Stratagene) and both strands sequenced using external (T7 and T3) and internal primers (DNAgency) on an automated sequencer at the Molecular Genetics Core Facility of the University of Texas Medical School. Sequence similarity searches were carried out with blast and beauty postprocessing by using the Drosophila genome database flybase, the National Center for Biotechnology Information, and the Human Genome Center at Baylor College of Medicine. Nucleotide and amino acid sequences were aligned with clustal w. Amino acid identity and homology comparisons were performed using the program seqvu 1.0.1 (GES scale). Analysis of promoter region sequence was carried out using macvector and the transfac database.
Histology and Tissue in Situ Hybridization.
B-galactosidase staining of whole mount and dissected tissues was as in ref. 10. Tissue in situ hybridizations were performed using digoxigenin-labeled probes of Thor-coding sequence, prepared as described in the Boehringer-Mannheim DNA labeling and detection kit and as in ref. 7 for embryos, larvae, and adults.
Northern Blot Analysis.
The Totally RNA Kit (Ambion) was used to extract RNA from each developmental stage of the Oregon R strain. The Totally RNA kit also was used to extract RNA from Oregon R and Thor mutant adults that were untreated, wounded with a sterile needle or injected with E. cloacae B12 through puncture with a septic needle. Wounded and infected flies were allowed to recover for 6 h at 25°C and visually checked for wound response by characteristic melanization around the puncture site before RNA was extracted. Formaldehyde gels and Northern blots were made as in ref. 15. Probes were for Cecropin, actin5C, and rp49 as in ref. 7, eIF4E (16) and Thor. Thor probes were both DNA and RNA, corresponding to cDNA and genomic DNA sequence, i.e., the 1.7-kb BglII plasmid rescue subclone. Radioactively labeled DNA probes were made using the Prime-a-gene kit (Promega) and antisense RNA probes were made using the RNA transcription kit (Ambion).
Results
Molecular Identification and Expression of Thor.
The Thor gene was initially identified based on a P{lacW} insertion located at cytological position 23F-24A that shows increased reporter gene expression in response to bacterial infection (10). To determine the molecular identity of Thor, we used plasmid rescue (13) to isolate genomic DNA fragments flanking the P{lacW} insertion, for a total of 14 kb (Fig. 1A). Restriction enzyme fragments of this DNA were used in tissue in situ hybridizations to whole mount embryos to define candidates for the region encoding Thor. Only the 1.7 kb immediately downstream of the insertion hybridized, and expression showed in the central nervous system, same as the B-galactosidase localization of the enhancer trap (10). This DNA fragment was then tested in a Northern blot analysis comparing RNA from wild-type adults with and without a bacterial infection. A band of 0.85 kb was detected that is present without an infection and strongly induced by infection (Fig. 2A). DNA sequencing analysis revealed that the 1.7 kb does include the entire coding region of Thor, and that one 423-bp intron interrupts the ORF that encodes a 117-aa protein (Fig. 1B and C). flybase clone GH19868 is a full-length Thor cDNA, starting at base 14 and ending at base 1139 of Fig. 1B, and Clot 7548 is a set of partial Thor cDNAs. The Thor protein is similar to the mammalian translational regulators known as 4E-BPs (Fig. 1C). Sequences corresponding to 4E-BPs also have been identified in zebrafish, the slime mold Dictyostelium discoideum and the parasite Schistosoma mansoni (Fig. 1C). THOR is most similar to mouse PHAS-II and human 4E-BP2, with 39% and 38% identity respectively, and 67.5% similarity for both. Of importance is the high conservation in the central region, residues 34–59 for THOR, as this includes the binding region of 4E-BPs to eIF4E. THOR has 66.5–70% identity with all sequences in this region, except for D. discoideum, which has 55.5% identity.
In mouse and human, two and three 4E-BPs, respectively, have been identified. Standard genome Southerns do not suggest another gene in Drosophila (data not shown), however, we do not have an explanation for the 2-kb transcript that shows on Northern blots with Thor probes (Fig. 2). It may be that the 2-kb transcript results from differential splicing or that it reflects cross-hybridization to transcripts from a different locus with sequence similarity. This transcript is, however, clearly not induced by infection (Fig. 2). In contrast, the 0.85-kb Thor transcript is not only induced by infection, it also is up-regulated to a lesser degree by wounding, as has been found for other immune-regulated genes (Fig. 2A). The main site of induction of the immune response is the fat body, which corresponds to the mammalian liver (for review, see ref. 3), and we have found that Thor is also up-regulated in the fat body by comparing dissected third instar larval fat bodies with and without infection (data not shown).
The developmental profile of wild-type Thor expression shows transcripts present throughout all stages of development, with a noticeable increase in the larval stages, especially the third instar (Fig. 2C). We have previously shown that B-galactosidase in the P{lacW} Thor strain localizes to the embryonic nervous system and to many tissues in larvae and adults (10). We have found the same results by tissue in situ hybridizations with Thor probes and extended the analysis to the reproductive system (Fig. 3). Fig. 3 shows Thor expression in the testes of third instar males and in the ovaries of adult females. This expression in the testes and ovarian nurse cells is part of a more complex pattern of expression in both the female and male reproductive systems (B. Andruss, S. Meller, and D.A.K., unpublished observations). The general expression of Thor and in particular the expression in the ovaries, in which there are intricate systems of translational regulation (17), are consistent with the role of Thor as a 4E-BP, but the role of a 4E-BP in the immune response is not consistent with or predicted by current views in immunity. Two important initial concerns are thus: (i) is Thor induction regulating cell growth as a secondary effect of the immune response? and (ii) Is Thor induction specifically immune induced?
Test for eIF4E Immune Induction.
An important question with regard to the possibilities of Thor induction being involved in cell growth regulation is whether or not eIF4E also is induced by infection. In mammalian cells, overexpression of eIF4E is associated with malignant transformation, and concomitant overexpression of 4E-BP has been shown to negate this overgrowth (for review see ref. 18). In the Drosophila immune response, large quantities of antimicrobial proteins are produced and one possibility is that eIF4E could be up-regulated to increase translation. In this scenario, Thor up-regulation would have the homeostatic function of producing more 4E-BP to keep growth regulation in balance. We therefore tested the hypothesis that eIF4E also is up-regulated by bacterial infection. We found that this is not the case, as Thor is up-regulated upon infection while the levels of eIF4E mRNA remain the same (Fig. 4). Therefore, if these two components are coordinately regulated, it is not at the level of transcription.
Thor-Promoter Analysis.
All of the promoter regions studied for Drosophila antimicrobial genes induced by infection have been found to have elements similar to those of immune inducible genes in mammals (for review, see refs. 2 and 3). Sequence analysis of the 5′-flanking region has determined that Thor has an array of these types of elements (Fig. 5). First of all, the Thor promoter has the canonical NFκB recognition sequence that has been shown to be essential for immune induction (for review, see refs. 2 and 3). Further, Thor has the GATA sequence associated with NFκB elements that has been also shown to be important for immune induction (19) and conserved in other Drosophila species (14). Additional sequences found upstream of Drosophila immune response genes have been also identified, in particular those involved in vertebrate cytokine regulation and liver specific expression (Fig. 5). transfac analysis (20) has identified more sequences related to liver-specific regulation, such as hepatocyte nuclear factor/forkhead, and also interferon-related regulatory sequences (Fig. 5).
Response of Mutant Thor Flies to Bacterial Infection.
The most critical test of immune response is for survival after infection. To determine the effect of Thor mutation on immune response, we identified Thor mutations and then subjected control and Thor mutant flies to different types of bacterial infection and observed their survival for 4 days.
The P{lacW} insertion that led to identifying Thor also resulted in the Thor1 mutation. P{lacW} inserted adjacent to the TATA box, separating the coding region from the promoter region (Fig. 1A), and Northern analysis of flies with this insertion reveals that only a small amount of the 0.85-kb Thor transcript is present, and it does not increase after infection (Fig. 2B). The P-element insertion has thus resulted in the production of the Thor1 mutation, a noninducible, very weakly expressing hypomorph. To control for background effects, we used a wild-type revertant of the Thor1 mutation, Thor1rv1, which was produced by precise excision of the P{lacW} insertion. To confirm that any differences between Thor1 and Thor1rv1 flies are the result of mutation of Thor, we also used a second Thor mutation, Thor2. In Thor2, P{lacW} also is excised, but leaving Thor still mutant because of imprecise excision that deleted bases between P{lacW} and the first B site (Fig. 1A). Thor1 and Thor2 mutants are homozygous viable and fertile, and in noninfected and sterile wounding controls, survival is similar to wild-type Oregon R flies (10; data not shown), Thor1rv1 and imd (Fig. 6A). Thor1rv1 survives like Oregon R and is referred to here as the designated wild-type control (wt in Fig. 6). As a control for susceptibility to infection, we used imd mutants. In similar experiments, flies with the imd mutation have been shown to be highly susceptible to bacterial infection, and imd clearly operates in controlling induction of antibacterial genes (5, 6, 8).
We found that survival of mutant Thor adults was similar to wild-type adults when infected by E. coli and E. cloacae B12 (Fig. 6A). Both bacterial types affected imd flies as expected, with on average 11% surviving 4 days after infection with E. cloacae B12 and 1% surviving with E. coli infection (Fig. 6A). After infection (4 days) with S. epidermidis, however, on average only 46% of Thor1 and 47% of Thor2 flies survived (Fig. 6B). Surprisingly, 66% of imd flies survived, which is much higher than Thor mutants and also the previously reported survival for imd flies, which was approximately 8% after E. coli infection (6). Tests with M. roseus showed that even wild-type flies are susceptible, with 47% surviving on average (Fig. 6C). Thor mutants and imd flies were both more susceptible, with 11% for Thor1, 16% for Thor2, and 2% for imd surviving on average 4 days after infection. The antibacterial response provides a strong defense, and failure of survival by mutants indicates that a critical facet of the response has been disrupted. Our results show that Thor mutants are immune compromised, and when subjected to some types of bacteria, the disruption of the immune response leads to failure of survival.
Discussion
Our initial screen for immune response genes was carried out without bias in the selection process, leading to the identification of a new type of gene involved in immunity. Thor is a member of the 4E-BP family, and it is induced in response to bacterial infection and, to a lesser extent, by wounding. Without an infection, Thor is expressed during all developmental stages, and transcripts localize to a variety of tissues. Promoter region sequences and infection induced expression of Thor in the fat body are consistent and correspond with the fat body being the major organ of the humoral response, but other tissues may also up-regulate Thor. The presence of potential interferon related regulatory sequences is interesting, particularly given the roles of interferon and translational regulation in viral infection. Further, the interferon consensus response element GAAANN portion of the Thor interferon-related regulatory sequences has been previously identified in the Diptericin promoter and specifically shown to enhance Diptericin-promoter activity (21).
In contrast to humoral immunity, translational regulation in cellular immunity is already indicated. For example, in Drosophila, translation has been studied by Watson et al. on lethal(1)aberrant immune response8, which encodes the homolog of human S6 ribosomal protein and causes cancerous overgrowth upon mutation (22), and on S6k, the kinase of RpS6 (23). In mouse T cells, activation correlates with changes in translation as well as transcription (24). In immunosuppressant drug studies, rapamycin has been found to block cell cycle progression and involve inhibiting 4E-BP1 phosphorylation and cap-dependent translation (see ref. 25).
The extent of the protective role of Thor up-regulation in the immune response was tested by using Thor mutants in infection survival experiments. While this type of experiment appears simple, it is actually difficult to perform and does not indicate the specific defect caused by a mutation. However, the function of the entire immune response to an infection is tested, and as such this is the best available method to begin assessing the role of Thor in immune function. We found that Thor mutants are immune compromised, with some bacterial types having little or no effect on survival and others strongly reducing survival capacity. Although four bacterial types is insufficient for a conclusion, the difference in effect does correlate with whether the bacteria are Gram-positive or Gram-negative. Lemaitre et al. (8) have demonstrated that Drosophila is sensitive to bacterial infection type and shows varying levels of induction for the different antibacterial protein genes, both for individual strains and generally for Gram-positive vs. Gram-negative. imd flies were expected to survive poorly with all types, yet imd survived well when infected with S. epidermidis and better than did Thor flies. This result is consistent with the observation that the imd pathway is preferentially activated by Gram-negative bacteria (8), and therefore a Gram-positive bacterial strain may be less likely to cause lethality in an imd mutant. Thor flies were the opposite, being more resistant to Gram-negative bacteria.
The sequence similarity of Thor with 4E-BP and the conservation of 4E-BP family members implicate a role for translational regulation in the immune response. The most straightforward hypotheses involve a role based on binding to eIF4E, as that is the most conserved region and defines what is known of the family in other systems. The fact that eIF4E is not also up-regulated by infection is intriguing in terms of the relative functions of these genes in regulating cell growth, and now in responding to infection. Because a 4E-BP or other translational component has not been previously found to be induced by infection, our results with Thor indicate that an unexpected system is operative in the immune response. As the death of imd flies appears to reflect the necessity of the induction of imd-regulated genes (5, 6), Thor lethality can be postulated to reflect the necessity of the translation of the relevant immune transcripts for a given type of bacterial infection. Thus, the function of Thor in immunity may be the preferential translation of immune transcripts. A primary mode used by viruses to subvert cellular translational machinery is an alternate, 5′-cap-independent initiation of translation through the use of specific 5′-untranslated region sequences, the internal ribosome entry sites, and dephosphorylation of eIF4E (26, 27). A model from other studies is thus that THOR would act to inhibit cap-dependent translation by eIF4E and to promote cap-independent translation. Given that in the immune response massive production of antimicrobial proteins is required, this leads to the testable hypothesis that translation of immune transcripts involves cap-independent mechanisms. Also, translation of mRNAs encoding proteins with counteractive effects could be suppressed. Alternatively, if translation of Thor is delayed after immune induction, then THOR could function to block translation, thereby shutting off the immune response.
Thor may function in immunological memory. A second infection has been observed to produce a stronger response than the first (28), and Thor may provide the mechanism to explain this form of, as is now termed here, immunological memory. This could be, for example, through sequestration of immune transcripts or blocking translation, as described above, with immune transcripts remaining stable for later translation. Immunological memory and preferential translation are also not mutually exclusive. For example, Dif has a 5′-untranslated region typical for alternate translational regulation, and Dif up-regulation already has been postulated to provide an explanation for a stronger second response (9).
In terms of other models, the heat shock response studied in many organisms provides an excellent model of both transcriptional and translational regulation for comparing to the Drosophila immune response. Heat shock mRNA is induced via heat shock sequence promoter elements, and translation of nonheat shock mRNA is repressed, whereas translation of heat shock mRNA is preferential, mediated by specific 5′-untranslated region sequences and appearing to involve cap-independent translation (for review, see refs. 29 and 30). Thor is a candidate member of an old, fundamental system that has developed to cope with stress and infections of various types.
Although Thor is most likely to function as a 4E-BP in the immune response, it may be that Thor has functions that are immune specific and not necessarily related to translational regulation. It is an open question as to whether additional 4E-BPs or other components in the 4E-BP pathway will also be found to be like Thor in having immune function. However, given the phylogenetic conservation of innate immunity, it is expected that this new component of immunity will also be conserved.
Acknowledgments
We thank David Caprette for bacterial strains, Bruno Lemaitre for Drosophila stocks, and Mathieu Miron, Pascal Lachance, Paul Lasko and Nahum Sonenberg for cDNA and sharing data before publication. We are especially appreciative of discussions with Kellie Watson, the assistance of Mikal Cline with infection experiments, and comments on the manuscript by Bernie Andruss and Kate Beckingham. This work is supported by American Cancer Society Grants IM697B and 9302006CIM and National Institutes of Health Grant R01GM61458 to D.A.K.
Abbreviations
- 4E-BP
4E-binding protein
- Dif
dorsal-related immunity factor
- eIF4E
eukaryotic initiation factor 4E
Footnotes
This paper was submitted directly (Track II) to the PNAS office.
Article published online before print: Proc. Natl. Acad. Sci. USA, 10.1073/pnas.100391597.
Article and publication date are at www.pnas.org/cgi/doi/10.1073/pnas.100391597
References
- 1.Kimbrell D A. BioEssays. 1991;13:657–663. doi: 10.1002/bies.950131207. [DOI] [PubMed] [Google Scholar]
- 2.Hultmark D. Trends Genet. 1993;9:178–183. doi: 10.1016/0168-9525(93)90165-e. [DOI] [PubMed] [Google Scholar]
- 3.Meister M, Lemaitre B, Hoffmann J A. BioEssays. 1997;19:1019–1026. doi: 10.1002/bies.950191112. [DOI] [PubMed] [Google Scholar]
- 4.Hoffmann J A, Kafatos F C, Janeway C A, Ezekowitz R A B. Science. 1999;284:1313–1318. doi: 10.1126/science.284.5418.1313. [DOI] [PubMed] [Google Scholar]
- 5.Lemaitre B, Kromer-Metzger E, Michaut L, Nicolas E, Meister M, Georgel P, Reichhart J M, Hoffmann J A. Proc Natl Acad Sci USA. 1995;92:9465–9469. doi: 10.1073/pnas.92.21.9465. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Lemaitre B, Nicolas E, Michaut L, Reichhart J M, Hoffmann J A. Cell. 1996;86:973–983. doi: 10.1016/s0092-8674(00)80172-5. [DOI] [PubMed] [Google Scholar]
- 7.Williams M J, Rodriguez A, Kimbrell D A, Eldon E D. EMBO J. 1997;16:6120–6130. doi: 10.1093/emboj/16.20.6120. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Lemaitre B, Reichhart J-M, Hoffmann J A. Proc Natl Acad Sci USA. 1997;94:14614–14619. doi: 10.1073/pnas.94.26.14614. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Ip Y T, Reach M, Engstrom Y, Kadalayil L, Cai H, Gonzalez-Crespo S, Tatei K, Levine M. Cell. 1993;75:753–763. doi: 10.1016/0092-8674(93)90495-c. [DOI] [PubMed] [Google Scholar]
- 10.Rodriguez A, Zhou Z, Tang M L, Meller S, Chen J, Bellen H, Kimbrell D A. Genetics. 1996;143:929–940. doi: 10.1093/genetics/143.2.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Hershey J W B, Matthews M B, Sonenberg N. Translational Control. Plainview, NY: Cold Spring Harbor Lab. Press; 1996. [Google Scholar]
- 12.Preiss T, Hentze M W. Curr Opin Genet Dev. 1999;9:515–521. doi: 10.1016/s0959-437x(99)00005-2. [DOI] [PubMed] [Google Scholar]
- 13.Wilson D, Bellen H J, Pearson R K, O'Kane C J, Grossniklaus U, Gehring W. Genes Dev. 1989;3:1301–1333. doi: 10.1101/gad.3.9.1301. [DOI] [PubMed] [Google Scholar]
- 14.Zhou X, Nguyen T, Kimbrell D A. J Mol Evol. 1997;44:272–281. doi: 10.1007/pl00006144. [DOI] [PubMed] [Google Scholar]
- 15.Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning: A Laboratory Manual. Plainview, NY: Cold Spring Harbor Lab. Press; 1989. [Google Scholar]
- 16.Lavoie C A, Lachance P E D, Sonenberg N, Lasko P. J Biol Chem. 1996;271:16393–16398. doi: 10.1074/jbc.271.27.16393. [DOI] [PubMed] [Google Scholar]
- 17.Stebbins-Boaz B, Richter J D. Crit Rev Eukaryot Gene Expr. 1997;7:73–94. doi: 10.1615/critreveukargeneexpr.v7.i1-2.50. [DOI] [PubMed] [Google Scholar]
- 18.Clemens M J, Bommer U A. Int J Bioc Cell Biol. 1999;31:1–23. doi: 10.1016/s1357-2725(98)00127-7. [DOI] [PubMed] [Google Scholar]
- 19.Kadalayil L, Petersen U M, Engstrom Y. Nucleic Acids Res. 1997;25:1233–1239. doi: 10.1093/nar/25.6.1233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Heinemeyer T, Chen X, Karas H, Kel A E, Kel O V, Liebich I, Meinhardt T, Reuter I, Schacherer F, Wingender E. Nucleic Acids Res. 1999;27:318–322. doi: 10.1093/nar/27.1.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Georgel P, Kappler C, Langley E, Gross I, Nicolas E, Reichhart J M, Hoffmann J A. Nucleic Acids Res. 1995;23:1140–1145. doi: 10.1093/nar/23.7.1140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Watson K L, Konrad K D, Woods D F, Bryant P J. Proc Natl Acad Sci USA. 1992;89:11302–11306. doi: 10.1073/pnas.89.23.11302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Watson K L, Chou M M, Bienis J, Gelbart W M, Erikson R L. Proc Natl Acad Sci USA. 1996;93:13694–13698. doi: 10.1073/pnas.93.24.13694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Garcia-Sanz J A, Mikultis W, Livingstone A, Lefkovits I, Muellner E W. FASEB J. 1998;12:299–306. doi: 10.1096/fasebj.12.3.299. [DOI] [PubMed] [Google Scholar]
- 25.Scott P H, Brunn G J, Kohn A D, Roth R A, Lawrence J C. Proc Natl Acad Sci USA. 1998;95:7772–7777. doi: 10.1073/pnas.95.13.7772. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Matthews M B. In: Translational Control. Hershey J W B, Matthews M B, Sonenberg N, editors. Plainview, NY: Cold Spring Harbor Lab. Press; 1996. pp. 505–548. [Google Scholar]
- 27.Sachs A B, Sarrow P, Hentze M W. Cell. 1997;89:831–838. doi: 10.1016/s0092-8674(00)80268-8. [DOI] [PubMed] [Google Scholar]
- 28.Boman H G, Nilsson I, Rasmussen B. Nature (London) 1972;237:232–235. doi: 10.1038/237232a0. [DOI] [PubMed] [Google Scholar]
- 29.Duncan R F. In: Translational Control. Hershey J W B, Matthews M B, Sonenberg N, editors. Cold Spring Harbor: Laboratory Press; 1996. pp. 271–294. [Google Scholar]
- 30.Vries R G J, Flynn A, Patel J C, Wang X M, Denton R M, Proud C G. J Biol Chem. 1997;272:32779–32784. doi: 10.1074/jbc.272.52.32779. [DOI] [PubMed] [Google Scholar]
- 31.Kappler C, Meister M, Lagueux M, Gateff E, Hoffmann J A, Reichhart J M. EMBO J. 1993;12:1561–1568. doi: 10.1002/j.1460-2075.1993.tb05800.x. [DOI] [PMC free article] [PubMed] [Google Scholar]